Merck Q1 earnings fall but beat expectations; 2026 guidance raised By Investing.com

Merck reported Q1 net profit of 669 million euros, down 9.4% year-on-year but ahead of expectations of 1.99 euros per share versus actual EPS of 2.11 euros. Net sales of 5.13 billion euros also beat the 5.09 billion-euro consensus, and the company raised FY26 guidance, lifting organic sales growth to 0%-3% from -1% to 2% and EPS to 7.50-8.20 euros from 7.10-8.00 euros. Strength in semiconductor materials, Life Science, and Mavenclad offset FX headwinds, which should support the stock.

Analysis

The market is likely underestimating how much of this beat is a mix-shift story rather than a clean cyclical inflection. AI/HPC exposure in the tools stack tends to carry better pricing power and lower cancellation risk than legacy industrial end-markets, so even a modest demand acceleration can produce outsized margin leverage over the next 2-3 quarters. That makes the earnings revision more durable than a simple macro beta trade, especially if semiconductor capex remains concentrated in leading-edge nodes.

The second-order winner is not just the company itself but the broader European semiconductor materials chain: improved order visibility at a key supplier usually supports sentiment for adjacent photoresists, specialty chemicals, and wafer-handling names with similar exposure to advanced packaging and fab buildouts. The loser is any competitor selling into mature-node or consumer-electronics-heavy channels, where pricing remains more vulnerable and FX can still erase volume gains. In healthcare, the implication is that pipeline/portfolio strength can now offset patent- or competition-related headwinds for longer than consensus models assume.

The contrarian point is that this is still a low-quality global tape for Europe: if FX stays adverse or the semiconductor cycle pauses, the current upgrade can look like a one-quarter reset rather than a durable rerating. Consensus may be too quick to extrapolate AI demand into a straight-line earnings upgrade, but too slow to appreciate that even a 1% EBITDA upside can matter for valuation when the stock has been range-bound on macro fears. The setup is strongest over the next 1-3 months, before investors fully re-anchor FY26 estimates.

Key Decisions for Investors

• Go long MS on weakness into the next 1-2 sessions; target a 5-8% rerating over 4-8 weeks if sell-side model upgrades follow, with downside capped by the upgraded guide.
• Pair trade: long MS / short a Europe-wide industrials basket with weaker semiconductor exposure over the next quarter; the relative setup should benefit from better estimate revisions and higher-quality mix.
• Add a tactical long in semiconductor materials and equipment beneficiaries with AI/HPC exposure for 1-3 months; use MS as a signal that the order environment is still holding, but keep position size modest because the move is still consensus-dependent.
• If already long European cyclicals, rotate out of names with high FX sensitivity and poor pricing power; the risk/reward now favors businesses where mix and guidance carry more weight than macro beta.
• For options traders, consider buying 1-2 month calls or call spreads on MS rather than outright stock if implied vol is still compressed; the catalyst is near-term estimate revision, not a multi-year thesis reset.